Back
Kymera Therapeutics Quote, Financials, Valuation and Earnings
Gold Set to Skyrocket as Fed Slashes Rates
Click here for the details on this incredible opportunity.
Buy
67
KYMR
Kymera Therapeutics
Last Price:
48.00
Seasonality Move:
69.6%
7 Day Trial
ALL ACCESS PASS
$
7
AI DIVIDENDS: No. 1 Way to Collect Passive Income
Click here to get it for free.Kymera Therapeutics Price Quote
$48.00
-0.49 (-1.01%)
(Updated: October 30, 2024 at 2:25 PM ET)
Kymera Therapeutics Key Stats
Buy
67
Kymera Therapeutics (KYMR)
is a Buy
Day range:
$47.75 - $49.16
52-week range:
$9.60 - $53.27
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
35.70
P/B ratio:
4.37%
Volume:
355.9K
Avg. volume:
430.7K
1-year change:
342.02%
Market cap:
$3B
Revenue:
$78.6M
EPS:
$-2.42
How Much Does Kymera Therapeutics Make?
-
How Much Are Kymera Therapeutics's Sales Annually?
KYMR Revenues are $78.6M -
How Much Profit Does Kymera Therapeutics's Make A Year?
KYMR net income is -$147M
Is Kymera Therapeutics Growing As A Company?
-
What Is Kymera Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.55% -
What Is Kymera Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Kymera Therapeutics Stock Price Performance
-
Did Kymera Therapeutics Stock Go Up Last Month?
Kymera Therapeutics share price went down by -0.41% last month -
Did KYMR's Share Price Rise Over The Last Year?
KYMR share price rose by 342.02% over the past 1 year
What Is Kymera Therapeutics 52-Week High & Low?
-
What Is Kymera Therapeutics’s 52-Week High Share Price?
Kymera Therapeutics has traded as high as $53.27 over the past 52 weeks -
What Is Kymera Therapeutics’s 52-Week Low Share Price?
Kymera Therapeutics has traded as low as $9.60 over the past 52 weeks
Kymera Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Kymera Therapeutics?
-
How Much Debt Does Kymera Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Kymera Therapeutics Have?
Cash and short term investments quarterly total is $510M -
What Is Kymera Therapeutics’s Book Value Per Share?
Book value per share is 11.12
Is Kymera Therapeutics Cash Flow Positive?
-
What Is KYMR Cash Flow From Operations?
Cash flow from operations (TTM) is -$106.1M -
What Is Kymera Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $356.9M -
What Is Kymera Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$235.5M
Kymera Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
KYMR return on invested capital is -30.1% -
What Is Kymera Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -23.18% -
What Is KYMR Return On Equity?
ROE is a measure of profitability and is -30.1%
Kymera Therapeutics Earnings Date & Stock Price
-
What Is Kymera Therapeutics's Stock Price Today?
A single share of KYMR can be purchased today for 48.49 -
What Is Kymera Therapeutics’s Stock Symbol?
Kymera Therapeutics trades on the nasdaq under the ticker symbol: KYMR -
When Is Kymera Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Kymera Therapeutics is scheduled on October 31, 2024 -
When Is KYMR's next ex-dividend date?
Kymera Therapeutics's next ex-dividend date is October 30, 2024 -
How To Buy Kymera Therapeutics Stock?
You can buy Kymera Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Kymera Therapeutics Competitors
-
Who Are Kymera Therapeutics's Competitors?
Below is a list of companies who compete with Kymera Therapeutics or are related in some way:
Kymera Therapeutics Dividend Yield
-
What Is KYMR Dividend Yield?
Kymera Therapeutics’s dividend yield currently is 0% -
What Is Kymera Therapeutics’s Payout Ratio?
Kymera Therapeutics’s payout ratio is 0% -
When Did Kymera Therapeutics Last Pay A Dividend?
The latest dividend pay date is October 30, 2024 -
What Is Kymera Therapeutics’s Dividend Per Share?
Kymera Therapeutics pays a dividend of $0.00 per share
Kymera Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | 12.01% |
| Revenue: | 55.33% | 104.31% |
Analyst Recommendations
| Buy Recommendations: | 10 |
|---|---|
| Hold Recommendations: | 4 |
| Sell Recommendations: | 0 |
| Price Target: | 55.88 |
| Upside from Last Price: | 15.23% |